Adverse effects associated with contraceptive implants: Incidence, prevention and management

Advances in Contraception

Volumn 14, Issue 1, 1998, Pages 1-13

  Singh, K ^a   Chye, G C ^a  

^a NATIONAL UNIVERSITY HOSPITAL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRACEPTIVE AGENT; LEVONORGESTREL;

BRAIN PSEUDOTUMOR; DRUG IMPLANT; DRUG SAFETY; FEMALE; HUMAN; IMPLANTATION; INFECTION; ISCHEMIC HEART DISEASE; MENSTRUATION DISORDER; MENTAL DISEASE; PATIENT COMPLIANCE; REVIEW; RISK FACTOR; STROKE; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ADOLESCENT; ADULT; BLOOD GLUCOSE; BLOOD PRESSURE; BODY WEIGHT; CONTRACEPTIVE AGENTS, FEMALE; DEPRESSION; DRUG IMPLANTS; FEMALE; HEADACHE; HUMANS; INFECTION; LIPID METABOLISM; LIPIDS; MENSTRUATION; MENSTRUATION DISTURBANCES; OVARIAN CYSTS; PREGNANCY; PREGNANCY, ECTOPIC; PSEUDOTUMOR CEREBRI; PURPURA, THROMBOTIC THROMBOCYTOPENIC; THROMBOCYTOPENIA;

EID: 0031954038     PISSN: 02674874     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006559124829     Document Type: Review

References (55)

1. Croxatto HB Norplant. Levonorgestrel-releasing contraceptive implant. Ann Med. 1993;25:155-60.
2. Segal SJ Contraceptive implants. In: Arulkumaran S, Ng SC. eds. Current Issues in Obstetrics and Gynaecology Singapore: Oxford University Press: 1996,271-82.
3. Wysowski DK. Green L Serious adverse events in Norplant users reported to the Food and Drug Administiations Med Watch Spontaneous Reporting System Obstet Gynaecol. 1995;85.538-42.
4. Diaz J, Faundes A, Olmos P, Diaz M. Bleeding complaints during the first year of Norplant use and their impact on removal rate. Contraception. 1996;53.91-5.
5. Pasquale SA, Knuppel RA, Owens AG, Bachmann GA. Irregular bleeding, body mass index and coital frequency in Norplant contraceptive users. Contraception 1994;50:109-16.
6. Shoupe D, Mishell DR, Bopp BL, Fielding M. The significance of bleeding patterns in Norplant implant users. Obstet Gynecol. 1991;77:256-60.
7. Sivin I. International experience with Norplant and Norplant-2 contraceptives. Stud Fam Plann. 1998,19:81-94.
8. Balogh SA, Klavon SL, Basnayake S, Puertollano N, Ramos RM, Grubb GS. Bleeding patterns and acceptability among Norplant users in two Asian countries. Contraception. 1989;39:541-53.
9. Datey S, Gaur LN, Saxena BN. Vaginal bleeding patterns of women using different contraceptive methods - An Indian experience. Contraception 1995;51:155-65.
10. Faundes A, Avarez F, Brache V, Jimenez E, Tejada AS. Hormonal changes associated with bleeding during low dose progestagen contraception delivered by Norplant subdermal implants. Adv Contracept. 1991;7:1-10.
11. Alvarez-Sanchez F, Brache V, Thevenin F, Cochon L, Faundes A. Hormonal treatment for bleeding irregularities in Norplant implant users. Am J Obstet Gynecol. 1996;174:919-22.
12. Waldman S et al. Norplant Levonorgestrel Implants A Summary of Scientific Data. New York, NY: The Population Council. 1990.
13. Mishell DR. Overview of contraception. In: Wallace EE, Zucker HA. eds. Reproductive Medicine and Surgery Baltimore, MD, USA: Moseby; 1995.289-316.
14. Darney PD, Atkinson E, Tanner S, MacPherson S, Hellerstein S, Alvarado A. Acceptance and perceptions of Norplants users in San Francisco, USA. Stud Fam Plann. 1990;21.152-62.
15. Cullins VE. Preliminary experience with Norplant in an inner city population. Contraception. 1993;47:193-203.
16. Croshy UD, Schwarz BE, Gluck KL, Heartwell SE. A preliminary report of Norplant implant insertion in large urban family planning program. Contraception. 1993;48:359-66.
17. Darney PD Hormonal implants: Contraception for a new century. Am J Obstet Gynecol. 1994;170:1536-43.
18. Sivin I. Contraception with Norplant implants. Hum Reprod. 1994;9:1818-26.
19. Moore LL, Valuck R, McDougall C, Fink W. A comparative study of one-year weight gain among users of medroxyprogesterone acetate. levonorgestrel implants and oral contraceptives. Contraception. 1995;52:215-20.
20. Spellacy WN, Birk SA. The effect of intrauterine devices, oral contraceptives, oestrogens and progestogens on blood pressure. Am J Obstet Gynecol. 1972;112:912-19.
21. Hall WD, Doublas MB, Blumenstein BA, Hatcher RA. Blood pressure and oral progestational agents: a prospective study of 119 black women. Am J Obstet Gynecol. 1980;136:344-8.
22. Shen Qifong, Lin Deliang, Jian Xiurong, Li Haifong, Zhang Zhongshu. Blood pressure changes and hormonal contraceptives. Contraception 1994;50:131-41.
23. Hatasaka H Implantable levonorgestrel contraception: 4 years of experience with Norplant. Clin Obstet Gynaecol 1995;38(4):859-71.
24. Nelson LA. Neutralizing pH of lidocaine reduces pain during Norplant system insertion procedures. Contraception. 1995;51.299-301.
25. Speroff L, Darney P Long-acting steroids methods. In: A Clinical Guide for Contraception. Baltimore, Maryland: Williams and Wilkins; 1992.
26. Sarma SP, Wamsher JG, Whitlock SW. Removal of deeply inserted, nonpalpable levonorgestrel (Norplant) implants. Contraception. 1996;53:159-61.
27. Twickler DM, Schwarz BG. Imaging of the levonorgestrel implantable contraceptive device. Am J Obstet Gynecol. 1992;167:572-3.
28. Diaz J, Rubin J, Faundes A et al. Comparison of local signs and symptoms after the insertion of Norplant implants with and without a scalpel. Contraception. 1991;44 217-21.
29. Zuber TJ, DeWitt DE, Patton DD. Skin damage associated with the Norplant contraceptive. J Fam Pract. 1992,34.613-16.
30. Klavon SL, Grubb GS. Insertion site complications during the first year of Norplant use. Contraception. 1990;41.27-37.
31. Alfa MJ, Sisler JJ, Harding GKM. Mycobacterium abscessus infection of a Norplant contraceptive implant site. Can Med Assoc. 1995;153.1293-6.
32. Konje J, Odukuya O, Otolorin E, Ewings P, Ladipo O. Carbohydrate metabolism before and after Norplant removal. Contraception. 1992;46:61-9.
33. Konje J, Otolorin E, Ladipo O. The effect of continuous subdermal levonorgestrel (Norplant) on carbohydrate metabolism. Am J Obstet Gynecol. 1992;166:15-19.
34. Konje J, Otolorin E, Ladipo OA. Changes in carbohydrate metabolism during 30 months of Norplant. Contraception. 1991;44:163-72.
35. Singh K, Viegas O, Ratnam S. Effect of Norplant implants on liver, lipid and carbohydrate metabolism. Contraception. 1992;45:141-53.
36. Singh K, Viegas O, Liew D, Singh P, Ratnam S. Two year follow-up of changes in clinical chemistry in Singaporean Norplant acceptors: Metabolic changes. Contraception. 1989;39:129-36.
37. Singh K, Viegas O, Loke D, Ratnam SS. Effect of Norplant-2 rods on liver lipid and carbohydrate metabolism. Contraception. 1992;45:463-72.
38. McDonald GW, Fisher GF, Burnham C. Reproducibility of the oral glucose tolerance test. Diabetes. 1965;14:473-80.
39. Koopersmith TB, Lobo RA. Insulin sensitivity is unaltered by the use of the Norplant subdermal implant contraceptive. Contraception. 1995;51:197-200.
40. Shamma FN, Rossi G, HaiHassan L et al. The effect of Norplant on glucose metabolism under hyperglycaemic hyperinsulinaemic conditions. Fertil Steril. 1995;63:767-72.
41. Shoupe D, Mishell DR. Norplant. Subdermal implant system for long-term contraception. Am J Obstet Gynecol. 1989;160:1286-92.
42. Croxatto HB, Diaz S, Robertson DN, Pavez M. Clinical chemistry in women treated with levonorgestrel implants (Norplant) or a TCu 200 IUD. Contraception. 1983;27:281-8.
43. Mainwaring R, Hales HA, Stevenson K et al. Metabolic parameter, bleeding and weight changes in US women using progestin only contraceptives. Contraception. 1995;51:149-53.
44. Otubu JAM, Towobola OA, Aisien AO, Ogunkeye OO. Effects of Norplant contraceptive subdermal implants on serum lipids and lipoproteins. Contraception. 1993;47:149-59.
45. Wagner KD. Major depression and anxiety disorders associated with Norplant. J Clin Psychiatr. 1996;57:152-7.
46. Lewis A, Hoghughi M. An evaluation of depression as a side effect of oral contraceptives. Br J Psychiatr. 1969;115:697-701.
47. Chaudhuri SK, Chattopadhyay RN, Maitra SK et al. Effects of progesterone on some brain neurotransmitters in intact rats. Ind J Physiol Pharmacol. 1992;36(4):255-8.
48. Grant EG, Davies JD. Effect of oral contraceptives on depressive mood changes and on endometrial monoamine oxidase and phosphates. Br Med J. 1968;3:777-80
49. Sheenan DV, Sheenan KH. Psychiatric aspects of oral contraceptive use. Psychiatr Ann. 1976;6:500-8.
50. Shaarawy M, Fayad M, Nagui AR et al Serotonin metabolism and depression in oral contraceptive users. Contraception. 1982;26:193-204.
51. Macs M, Claes M, Schotte C et al. Disturbances in dexamethasone suppression test and lower availability of L-tryptophan and tyrosine in early puerperium and in women under contraceptive therapy. J Psychosom Res. 1992;36:191-7.
52. Alder JB, Fraunfelder FT. Levonorgestrel implants and intracranial hypertension. N Eng J Med. 1995;332:1720-1
53. Radhakrishnan K, Ahlskog JE, Cross SA, Kurland LT, O'Fallon WM. Idiopathic intracranial hypertension (pseudotumour cerebri): descriptive epidemiology in Rochester, Minn 1976 to 1990. Arch Neurol. 1993;50:78-80.
54. Ruggenenti P, Remuzzi G. Thrombotic thrombocytopenic purpura and related disorders. Hematol Oncol Clin N Am. 1990;4:219-41.
55. Fraser JL, Millenson M, Malynn ER, Uhl L, Kruskall MS. Possible association between the Norplant contraceptive system and thrombotic thrombocytopenic purpura. Obstet Gynaecol. 1996;87:860-3.